Yahoo Finance 
Global Idiopathic Pulmonary Fibrosis Disease Treatment Markets, 2018-2019 & 2020-2024
Dublin, Sept. 08, 2021 (GLOBE NEWSWIRE) -- The "Idiopathic Pulmonary Fibrosis Disease Treatment: Global Markets" report has been added to ResearchAndMarkets.com's offering.
The current report provides detailed coverage of IPF. This report will provide perspective on the drugs and therapies used for the management of IPF, including forecast trends and sales through 2024. Important manufacturers, technologies and factors influencing demand are discussed.
The market has been segregated geographically into the U.S., Japan and five major European markets (Germany, France, Italy, Spain, and the U.K.). For market estimates, data has been provided for the year 2018 as the base year, 2019 and then forecast for 2024.
The Report Includes:
An overview of the global markets for idiopathic pulmonary fibrosis (IPF) disease treatment
Analyses of the global market trends, with corresponding market analysis data for 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2024
Estimation of market size and market share analysis of IPF chronic disease on the basis of type of therapeutics and geography
Insights into the market trends and opportunities, drivers and restraints, regulatory framework, epidemiology, complications, and prevalence of this chronic lung disease
Company profiles of the market leading participants within the pharmaceuticals industry
Key Topics Covered:
Chapter 1 Introduction
Reasons for Doing this Study
Scope of Report
Information Sources
Methodology
Analyst's Credentials
Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Drug Development and Approval Process
Introduction
Drug Discovery Process
Drug Definition
Drug Development Regulations
Classification of Techniques Used in Drug Discovery
High-Throughput Screening
Bioanalytical Instruments for Drug Discovery
Cell-Based Assays and Reagents for Drug Discovery
Proteomics Drug Discovery Tools
Genomics Drug Discovery Tools
Bioinformatics as a Platform for Drug Discovery
Others: Metabolomics, Combinatorial Chemistry, Systems Biology, and Nanotechnology
Chapter 4 Disease Overview
Etiology
Pathogenesis
Symptoms
Comorbidities
Risk Factors
Environmental
Genetic
Epigenetic Alterations
Aging
Chapter 5 Disease Management and Treatment
Diagnosis of Idiopathic Pulmonary Fibrosis
Diagnostic Criteria for IPF
Treatments for IPF
Lifestyle Changes
Oxygen
Medications
Pulmonary Rehabilitation
Lung Transplant
Chapter 6 Marketed Drugs for Idiopathic Pulmonary Fibrosis
Introduction
Overview of Products
Esbriet Drug Profile
Ofev Drug Profile
Chapter 7 Product Forecast for Idiopathic Pulmonary Fibrosis
Esbriet (Pirfenidone)
Ofev (Nintedanib)
Chapter 8 Product Pipeline for Idiopathic Pulmonary Fibrosis
Product Pipeline for Idiopathic Pulmonary Fibrosis
Chapter 9 Appendix: Acronyms
Companies Mentioned
Boehringer Ingelheim Gmbh
Roche
For more information about this report visit https://www.researchandmarkets.com/r/qpqt29
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
